Business
Virtual Tumour Proposal
Virtual Tumour Proposal.
About this update from Physiomics Plc
[{"type":"text","content":"\n \nRNS Number : 6814U Physiomics PLC 04 December 2013 \n \n\nPhysiomics plc \n(\"Physiomics\") or (\"the Company\")\n \nNew Agreement to advance inhibitor of novel target with global pharma company\nPhysiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has signed a substantial new contract with a major global pharmaceutical company. The programme of studies will begin immediately and take an estimated 9 months to reach a conclusion. Physiomics will determine the optimal dosing regimen of a new compound currently under development by this client. This compound has been shown to block a cellular pathway implicated in cancer growth. The Company will also determine the optimal chemotherapy combination partner in order to maximise the cancer-killing effects.\nThe project will be performed on a fee-for-service basis.\nDr Mark Chadwick, CEO of Physiomics, commented:\n\"We are delighted to be working with this global pharma on a new target. This is the second such project we have performed for them using the pre-clinical version of Virtual Tumour and further develops a strong relationship based on positive results.\"\n \nEnquiries:\n \nPhysiomics plc \nDr Mark Chadwick, CEO\n+44 (0)1865 784 980\n \n \nWH Ireland Limited (broker/nomad)\nKaty Mitchell\n+44 (0) 161 832 2174\n \n \n \n \nAbout Physiomics plc\n \nPhysiomics (AIM:PYC) is a computational systems biology services company applying simulations of cell behaviour to drug development to reduce the high attrition rates of clinical trials. 80-90 per cent of all clinical drug candidates fail to reach the market and estimates show that an overall ten per cent improvement in success rates could reduce the cost of one drug's development by as much as $242 million, from the current estimate of around $800 million1.\n \nPhysiomics develops computational systems biology models to predict and understand cancer drug efficacy from pre-clinical research to clinical development. Physiom...